Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hassan M Heshmati

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Frontiers in Endocrinology|January 31, 2024
Interactions between COVID-19 infection and diabetesHassan M Heshmati
European Journal of Endocrinology|October 3, 2012
Mechanisms in endocrinology. Role of emotional stress in the pathophysiology of Graves' diseaseGéraldine Falgarone, Hassan M Heshmati, Régis Cohen, et al.
JAMA|February 16, 2006
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trialF Xavier Pi-Sunyer, Louis J Aronne, Hassan M Heshmati, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonistAlain Soupart, Peter Gross, Jean-Jacques Legros, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 5, 2002
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal womenHassan M Heshmati, Sundeep Khosla, Simon P Robins, et al.
Canadian Journal of Physiology and Pharmacology|August 2, 2018
Effect of a nonsystemic, orally administered hydrogel, GS100, on metformin pharmacokineticsLorien E Urban, Denis Audet, Eyal S Ron, et al.
Obesity (Silver Spring, Md.)|November 14, 2018
A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight LossFrank L Greenway, Louis J Aronne, Anne Raben, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Frontiers in Endocrinology|January 31, 2024
Interactions between COVID-19 infection and diabetesHassan M Heshmati
European Journal of Endocrinology|October 3, 2012
Mechanisms in endocrinology. Role of emotional stress in the pathophysiology of Graves' diseaseGéraldine Falgarone, Hassan M Heshmati, Régis Cohen, et al.
JAMA|February 16, 2006
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trialF Xavier Pi-Sunyer, Louis J Aronne, Hassan M Heshmati, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonistAlain Soupart, Peter Gross, Jean-Jacques Legros, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 5, 2002
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal womenHassan M Heshmati, Sundeep Khosla, Simon P Robins, et al.
Canadian Journal of Physiology and Pharmacology|August 2, 2018
Effect of a nonsystemic, orally administered hydrogel, GS100, on metformin pharmacokineticsLorien E Urban, Denis Audet, Eyal S Ron, et al.
Obesity (Silver Spring, Md.)|November 14, 2018
A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight LossFrank L Greenway, Louis J Aronne, Anne Raben, et al.
Pageof 1